Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Rad R, Cadiñanos J, Rad L, et al. A genetic progression model of braf-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell. 2013;24:15–29.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Ramadas K, Qiao Y. Managing the changing burden of cancer in Asia. BMC Med. 2014;12:3.
   PubMed Web of Science ®Google Scholar
• Velde CJHVD, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum . Eur J Cancer. 2014;50:1.e1–1e.34.
   Web of Science ®Google Scholar
• Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–1068.
   PubMed Web of Science ®Google Scholar
• Hu Q, Baeg GH. Role of epigenome in tumorigenesis and drug resistance. Food Chem Toxicol. 2017;109:663–668.
   PubMed Web of Science ®Google Scholar
• Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13:679.
   PubMed Web of Science ®Google Scholar
• Yong WM, Lee S, Park BW, et al. S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer. 2013;13:1–7.
   PubMed Web of Science ®Google Scholar
• Von MG, Rezai M, Fasching PA, et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40–GeparQuattro). Ann Oncol. 2014;25:81.
   PubMed Web of Science ®Google Scholar
• Iwata H, Sato N, Masuda N, et al. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol. 2011;41:867–875.
   PubMed Web of Science ®Google Scholar
• Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology. 1994;106:899.
   PubMed Web of Science ®Google Scholar
• Gao J, Qiu Y, Liu S, et al. Knockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2. PLoS One. 2014;9:e102590.
   PubMed Web of Science ®Google Scholar
• Boissan M, Dabernat S, Peuchant E, et al. The mammalian Nm23/NDPK family: from metastasis control to cilia movement. Mol Cell Biochem. 2009;329:51–62.
   PubMed Web of Science ®Google Scholar
• Stahl JA, Leone A, Rosengard AM, et al. Identification of a second human nm23 gene, nm23-H2. Cancer Res. 1991;51:445.
   PubMed Web of Science ®Google Scholar
• Veenstra M. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene. 2002;21:2097.
   PubMed Web of Science ®Google Scholar
• Flørenes VA, Aamdal S, Myklebost O, et al. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992;52:6088–6091.
   PubMed Web of Science ®Google Scholar
• Oda Y, Naka T, Takeshita M, et al. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol. 2000;31:709–716.
   PubMed Web of Science ®Google Scholar
• Leone A, Seeger RC, Hong CM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene. 1993;8:855–865.
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Noma T, et al. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res. 1995;55:652–657.
   PubMed Web of Science ®Google Scholar
• Dannenberg JH, Berns A. Drugging drug resistance. Cell. 2010;141:18–20.
   PubMed Web of Science ®Google Scholar
• Turner NC, Reisfilho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13:e178.
   PubMed Web of Science ®Google Scholar
• Song MA, Tiirikainen M, Kwee S, et al. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One. 2013;8:e55761.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang A, Wei L, et al. NME2 reduces proliferation, migration and invasion of gastric cancer cells to limit metastasis. PLoS One. 2015;10:e0115968.
   PubMed Web of Science ®Google Scholar
• Kidd EA, Yu J, Li X, et al. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res. 2005;11:2612–2619.
   PubMed Web of Science ®Google Scholar
• Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 1994;54:1825.
   PubMed Web of Science ®Google Scholar
• Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151:68–79.
   PubMed Web of Science ®Google Scholar
• Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev. 2010;20:91–95.
   PubMed Web of Science ®Google Scholar
• Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17:1115–1129.
   PubMed Web of Science ®Google Scholar
• Berberich SJ, Postel EH. PuF/NM23-H2/NDPK-B transactivates a human c-myc promoter-CAT gene via a functional nuclease hypersensitive element. Oncogene. 1995;10:2343–2347.
   PubMed Web of Science ®Google Scholar
• Thakur RK, Kumar P, Halder K, et al. Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within c-MYC promoter nuclease hypersensitive element induces c-MYC expression. Nucleic Acids Res. 2009;37:172.
   PubMed Web of Science ®Google Scholar
• Bouvard C, Lim SM, Ludka J, et al. Small molecule selectively suppresses MYC transcription in cancer cells. Proc Natl Acad Sci USA. 2017;114:3497–3502.
   PubMed Web of Science ®Google Scholar
• Doorn JA, Maser E, Blum A, et al. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry. 2004;43:13106–13114.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Kezuka C, Morikawa Y, et al. Up-regulation of carbonyl reductase 1 renders development of doxorubicin resistance in human gastrointestinal cancers. Biol Pharm Bull. 2015;38:1309–1319.
   PubMed Web of Science ®Google Scholar
• Bushey RT, Chen G, Blevins-Primeau AS, et al. Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis. Pharmacogenet Genom. 2011;21:55–65.
   PubMed Web of Science ®Google Scholar
• Shen H, Xu J, Zhao S, et al. ShRNA-mediated silencing of the RFC3 gene suppress ovarian tumor cells proliferation. Int J Clin Exp Pathol. 2015;8:8968–8975.
   PubMed Web of Science ®Google Scholar